PEYKER TEMİZ, GİZEM AKKAŞ, NALAN NEŞE, FAZİLET UĞUR DUMAN, CANSU KARAKAŞ, YAMAÇ ERHAN

Determination of apoptosis and cell cycle modulators (p16, p21, p27, p53, BCL-2,Bax, BCL-xL, and cyclin D1) in thyroid follicular carcinoma, follicular adenoma,and adenomatous nodules via a tissue microarray method

Background/aim: To identify the role of gene products associated with apoptosis and cell cycle in the pathogenesis of thyroid follicular neoplasm. Materials and methods: Thirty follicular adenomas (FAs), 16 follicular carcinomas (FCs), and 20 adenomatous nodules (ANs) were investigated with immunohistochemical staining of p16, p21, p27, p53, Bcl-2, Bax, Bcl-xL, and cyclin D1 via a tissue microarray method. Results: Bcl-2 showed a significant difference between the benign groups (AN and FA) and the malignant group (FC). Bax was significantly higher in the FC group. p53 was lowest in the AN group and highest in the FC group with significant differences between the groups. p16 was significantly higher in the FC group than in the other groups. There was a significant difference between the AN group and neoplastic lesions in terms of p21 staining. The number of cases with positive p27 was lower in the AN group than the neoplastic groups. There was no significant difference in terms of Bcl-xL and cyclin D1. Conclusion: Cell cycle modulators, led by the Bcl-2 family, played an important role in the pathogenesis of thyroid follicular neoplasm, and p53, p16, and p21 in particular played a role in the carcinogenesis of FC.

Anahtar Kelimeler:

Thyroid, follicular neoplasm, p16, p21, p27, p53, Bcl-2, Bax, Bcl-XL, Cyclin D1, immunohistochemistry, tissue microarray

Determination of apoptosis and cell cycle modulators (p16, p21, p27, p53, BCL-2, Bax, BCL-xL, and cyclin D1) in thyroid follicular carcinoma, follicular adenoma, and adenomatous nodules via a tissue microarray method

Keywords:

Thyroid, follicular neoplasm, p16, p21, p27, p53, Bcl-2, Bax, Bcl-XL, Cyclin D1, immunohistochemistry, tissue microarray,

PDF

___

Cvejic D, Selemetjev S, Savin S, Paunovic I, Petrovic I, Tatic S. Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. Pathology 2008; 40: 475–480.
Branet F, Brousset P, Krajewski S, Schlaifer D, Selves J, Reed JC, Caron P. Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J Clin Endocrinol Metab 1996; 81: 2726–2730.
Martínez-Brocca MA, Castilla C, Navarro E, Amaya MJ, Travado P, Japón MA, Sáez C. Clinicopathological correlations of Bcl-xL and Bax expression in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2008; 68: 190–197.
Zedenius J, Larsson C, Wallin G, Bäckdahl M, Aspenblad U, Höög A, Bİrresen AL, Auer G. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. Thyroid 1996; 6: 1–9.
Ferenc T, Lewiński A, Lange D, Niewiadomska H, Sygut J, Sporny S, Jarzab B, Sałacińska-Loś E, Kulig A, Włoch J. Analysis of P53 and P21WAF1 proteins expression in follicular thyroid tumors. Pol J Pathol 2004; 55: 133–141.
Morita N, Ikeda Y, Takami H. Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg 2008; 32: 2617–2622.
Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, Machinami R. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 1993; 17: 375–381.
Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S, Miya A, Mori T, Nishisho I, Takai S. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 1992; 83: 1293–1298.
Lange D, Ferenc T, Niewiadomska H, Włoch J, Turska M, Burkacka J, Kula D, Lewiński A, Jarzab B. Prognostic significance of selected oncogene and suppressor gene expression in follicular thyroid carcinoma. Wiad Lek 2001; 54: 72–78 (in Polish with English abstract).
Nasir A, Catalano E, Calafati S, Cantor A, Kaiser HE, Coppola D. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. In Vivo 2004; 18: 189–195.
Nikiforov YE, Gnepp DR. Pathomorphology of thyroid gland associated with radiation exposure: the Chernobyl experience and review of the literature. Adv Anat Pathol 1999; 6: 78–91.
Zafon C, Obiols G, Castellví J, Tallada N, Baena JA, Simó R, Mesa J. Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology 2007; 50: 225–231.
Godballe C, Asschenfeldt P, Jİrgensen KE, Bastholt L, Clausen PP, Hansen TP, Hansen O, Bentzen SM. Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. Laryngoscope 1998; 108: 243–249.
Ho YS, Tseng SC, Chin TY, Hsieh LL, Lin JD. p53 gene mutation in thyroid carcinoma. Cancer Lett 1996; 103: 57–63.
Puglisi F, Cesselli D, Damante G, Pellizzari L, Beltrami CA, Di Loreto C. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases. Anticancer Res 2000; 20: 311– 316.
Farid P, Gomb SZ, Péter I, Szende B. bcl2, p53 and bax in thyroid tumors and their relation to apoptosis. Neoplasma 2001; 48: 299–301.
Lam AK, Lo CY, Leung P, Lang BH, Chan WF, Luk JM. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma. Ann Surg Oncol 2007; 14: 1772–1779.
Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA. Diagnostic value of differential expression of CK19, galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 2006; 17: 225–234.
Boltze C, Zack S, Quednow C, Bettge S, Roessner A, Schneider- Stock R. Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. Pathol Res Pract 2003; 199: 399–404.
Ito Y, Kobayashi T, Takeda T, Komoike Y, Wakasugi E, Tamaki Y, Tsujimoto M, Matsuura N, Monden M. Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues. Br J Cancer 1996; 74: 1269–1274.
Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995; 76: 1643–1654.
Basolo F, Pinchera A, Fugazzola L, Fontanini G, Elisei R, Romei C, Pacini F. Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. Eur J Cancer 1994; 30: 171–174.
Okayasu I, Osakabe T, Onozawa M, Mikami T, Fujiwara M. p53 and p21 (WAF1) expression in lymphocytic thyroiditis and thyroid tumors. Clin Immunol Immunopathol 1998; 88: 183–191.
Erickson LA, Yousef OM, Jin L, Lohse CM, Pankratz VS, Lloyd RV. p27kip1 expression distinguishes papillary hyperplasia in Graves’ disease from papillary thyroid carcinoma. Mod Pathol 2000; 13: 1014–1019.
Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998; 11: 169–174.
Resnick MB, Schacter P, Finkelstein Y, Kellner Y, Cohen O. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod Pathol 1998; 11: 735–739.
Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 2002; 87: 1814–1818.
Pesutić-Pisac V, Punda A, Gluncić I, Bedeković V, Pranić- Kragić A, Kunac N. Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. Croat Med J 2008; 49: 643–649.
Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, Viglietto G, Palombini L. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol 2007; 60: 377–381.
Maynes LJ, Hutzler MJ, Patwardhan NA, Wang S, Khan A. Cell cycle regulatory proteins p27(kip), cyclins Dl and E and proliferative activity in oncocytic Hurthle Cell) lesions of the thyroid. Endocr Pathol 2000; 11: 331–340.
Volante M, Croce S, Pecchioni C, Papotti M. E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors. Mod Pathol 202; 15: 1038–1043.
Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA, Khan A. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol 2000; 13: 882– 887.
Erickson LA, Jin L, Goellner JR, Lohse C, Pankratz VS, Zukerberg LR, Thompson GB, van Heerden JA, Grant CS, Lloyd RV. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol 2000; 13: 186–192.
Wang S, Wuu J, Savas L, Patwardhan N, Khan A. The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol 1998; 29: 1304–1309.
Lazzereschi D, Sambuco L, Carnovale Scalzo C, Ranieri A, Mincione G, Nardi F, Colletta G. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 1998; 76: 806–811.
Londero SC, Godballe C, Krogdahl A, Bastholt L, Specht L, Sİrensen CH, Pedersen HB, Pedersen U, Christiansen P. Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? Acta Oncol 2008; 47: 451–457.
Khoo M, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin End Met 2002; 87: 1810–1813.
Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 2002; 198: 157–162.
Ferenc T, Lewiński A, Lange D, Niewiadomska H, Sygut J, Sporny S, Jarzab B, Satacińska-Los E, Kulig A, Włoch J. Analysis of cyclin D1 and retinoblastoma protein immunoreactivity in follicular thyroid tumors. Pol J Pathol 2005; 56: 27–35.